Analysts predict that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) will announce sales of $21.92 million for the current quarter, according to Zacks. Five analysts have made estimates for Deciphera Pharmaceuticals’ earnings, with the highest sales estimate coming in at $26.30 million and the lowest estimate coming in at $18.50 million. Deciphera Pharmaceuticals reported sales of $60,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 36,433.3%. The firm is scheduled to report its next quarterly earnings report on Tuesday, May 4th.
According to Zacks, analysts expect that Deciphera Pharmaceuticals will report full year sales of $119.12 million for the current year, with estimates ranging from $91.49 million to $160.00 million. For the next year, analysts forecast that the business will report sales of $255.81 million, with estimates ranging from $203.50 million to $317.30 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Deciphera Pharmaceuticals.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Monday, February 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.16) by $0.06. The company had revenue of $19.49 million during the quarter, compared to analysts’ expectations of $18.68 million.
Shares of DCPH traded down $1.80 during trading hours on Wednesday, reaching $45.20. The company had a trading volume of 524,158 shares, compared to its average volume of 437,042. The firm has a 50 day simple moving average of $44.08 and a 200-day simple moving average of $52.45. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of -9.04 and a beta of 1.49. Deciphera Pharmaceuticals has a 12-month low of $39.42 and a 12-month high of $68.40.
In related news, Director James Arthur Bristol sold 14,700 shares of the firm’s stock in a transaction that occurred on Monday, April 12th. The shares were sold at an average price of $43.84, for a total value of $644,448.00. Following the transaction, the director now owns 14,700 shares in the company, valued at $644,448. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael Douglas Taylor sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 1st. The shares were sold at an average price of $45.57, for a total transaction of $364,560.00. Following the completion of the transaction, the director now owns 8,000 shares in the company, valued at approximately $364,560. The disclosure for this sale can be found here. 7.02% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Hong Kong Ltd bought a new stake in shares of Deciphera Pharmaceuticals in the third quarter worth $53,000. Penserra Capital Management LLC boosted its holdings in Deciphera Pharmaceuticals by 170.7% in the fourth quarter. Penserra Capital Management LLC now owns 1,305 shares of the company’s stock worth $74,000 after purchasing an additional 823 shares during the period. Great West Life Assurance Co. Can boosted its holdings in Deciphera Pharmaceuticals by 1,766.8% in the third quarter. Great West Life Assurance Co. Can now owns 43,794 shares of the company’s stock worth $95,000 after purchasing an additional 41,448 shares during the period. Sowell Financial Services LLC boosted its holdings in Deciphera Pharmaceuticals by 17.4% in the fourth quarter. Sowell Financial Services LLC now owns 1,992 shares of the company’s stock worth $114,000 after purchasing an additional 295 shares during the period. Finally, Pacer Advisors Inc. boosted its holdings in Deciphera Pharmaceuticals by 14.9% in the fourth quarter. Pacer Advisors Inc. now owns 2,226 shares of the company’s stock worth $127,000 after purchasing an additional 288 shares during the period. Institutional investors own 73.61% of the company’s stock.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.